Anzeige
Mehr »
Samstag, 31.05.2025 - Börsentäglich über 12.000 News
Könnte diese Penny-Aktie das nächste 12 € Perpetua werden?! Verpassen Sie nicht den Antimon-Boom!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LGJ2 | ISIN: FR0004163111 | Ticker-Symbol: XUP
Tradegate
30.05.25 | 14:53
4,030 Euro
+0,15 % +0,006
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENFIT SA Chart 1 Jahr
5-Tage-Chart
GENFIT SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,9584,08213:03
3,9944,05230.05.

Aktuelle News zur GENFIT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.05.Genfit S.A. reports Q1 results3
22.05.GENFIT S.A.: GENFIT Reports First Quarter 2025 Financial Information245Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...
► Artikel lesen
22.05.Genfit S.A. - 6-K, Report of foreign issuer2
20.05.GENFIT S.A.: GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo in Italy145Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients...
► Artikel lesen
14.05.GENFIT S.A.: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)911Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients...
► Artikel lesen
14.05.Genfit S.A. - 6-K, Report of foreign issuer-
GENFIT Aktie jetzt für 0€ handeln
07.05.GENFIT S.A.: GENFIT Annual Combined General Meeting of June 17, 2025 - Availability of Preparatory Documents2
05.05.Genfit S.A. - 6-K, Report of foreign issuer4
05.05.GENFIT S.A.: GENFIT to Present Latest ACLF Research at EASL Congress 20252
29.04.GENFIT S.A.: GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F1
29.04.Genfit S.A. - 20-F, Annual and transition report of foreign private issuers-
28.04.GENFIT S.A.: Positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025186Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients...
► Artikel lesen
24.04.Genfit S.A. GAAP EPS of -€0.58, revenue of €38.18M3
24.04.GENFIT S.A.: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update379Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a...
► Artikel lesen
24.04.Genfit S.A. - 6-K, Report of foreign issuer2
20.03.GENFIT S.A.: GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders1.008GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million upfront payment with potential for an additional €55 million...
► Artikel lesen
20.03.Genfit S.A. - 6-K, Report of foreign issuer1
10.03.GENFIT S.A.: Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs127All resolutions approved by bondholders Closing of Royalty Financing and receipt of first €130 million instalment expected shortlyUpon closing of the Royalty Financing, GENFIT will implement the Repurchase...
► Artikel lesen
10.03.Genfit S.A. - 6-K, Report of foreign issuer2
27.02.GENFIT S.A.: GENFIT Announces Revenues and Cash Position as of December 31, 2024126Cash and cash equivalents totaled €81.8 million as of December 31, 2024Revenues amounted to €67.0 million as of December 31, 2024 including the €48.7 million milestone upon first sale of Ipsen's Iqirvo®...
► Artikel lesen
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1